Last update Oct. 1, 2023

C17H18N4O,HCl

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Alosetron is a 5-HT3 antagonist used for the treatment of irritable bowel syndrome (IBS) with predominantly severe diarrhea in women. Oral administration twice daily.

At the time of the last update, we found no published data on its excretion in breast milk.

Its pharmacokinetic data (very large volume of distribution and mode high percentage of binding to plasma proteins) make it unlikely to pass into breast milk in clinically significant quantities.

Its low oral bioavailability (even lower if taken with food) makes it difficult to pass into infant plasma from ingested breast milk, except in premature infants and the immediate neonatal period where there may be greater intestinal permeability.

Possible exposure can be decreased by waiting 3 hours after taking the drug to resume breastfeeding.

Alternatives

We do not have alternatives for C17H18N4O,HCl.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

C17H18N4O,HCl is Alosetron Hydrochloride in Molecular formula.

Is written in other languages:

Tradenames

Main tradenames from several countries containing C17H18N4O,HCl in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 50 - 60 %
Molecular weight 331 daltons
Protein Binding 82 %
VD 0.9 - 1.4 l/Kg
pKa 13.32 -
Tmax 1 hours
1.5 hours

References

  1. Alosetron Data Sheet 2010 Full text (in our servers)
  2. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006 Jul;131(1):283-311. Review. Abstract Full text (link to original source) Full text (in our servers)
  3. Andresen V, Hollerbach S. Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome? Drug Saf. 2004 Abstract

Total visits

125

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM